Gossamer Bio, Inc. announced that the U.S. Food and Drug Administration (the FDA) has placed a partial clinical hold on all trials of GB5121, in response to serious adverse events that have been observed in the Phase 1b/2 STAR-CNS study, including atrial fibrillation, a sudden death event and a fatal intracranial hemorrhage. The Company previously announced that it had paused enrollment of the Phase 1b/2 STAR-CNS Study based on the benefit /risk profile observed to date and a prioritization of resources to support the Company's seralutinib program. Based on the foregoing factors, the Company has decided to terminate all ongoing studies and discontinue development of GB5121.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6199 USD | -2.65% | -9.28% | -32.07% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.07% | 140M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+44.98% | 40.47B | |
-10.87% | 27.17B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- GOSS Stock
- News Gossamer Bio, Inc.
- Gossamer Bio Inc. Announces FDA has Placed a Partial Clinical Hold on All Trials of GB5121 in Response to Serious Adverse Events